Aurinia Pharmaceuticals ((AUPH)) announced an update on their ongoing clinical study.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Study Overview: Aurinia Pharmaceuticals is conducting a study titled A Double-Blind, Placebo-Controlled, Dose Escalation Study to Assess the Efficacy, Safety and Pharmacokinetics of Voclosporin in Adolescent and Pediatric Subjects With Lupus Nephritis. The study aims to evaluate the efficacy and safety of voclosporin in achieving renal response in young patients with active lupus nephritis over 24 weeks, highlighting its potential significance in treating this condition.
Intervention/Treatment: The study tests voclosporin, a calcineurin inhibitor, administered in varying doses against a placebo. The goal is to determine its effectiveness in treating lupus nephritis in adolescents and children.
Study Design: This Phase 3 interventional study is randomized and follows a sequential intervention model. It employs a quadruple masking approach, ensuring that participants, care providers, investigators, and outcome assessors are blinded during the initial phase. The primary purpose is treatment.
Study Timeline: The study began on March 11, 2022, and is currently recruiting. The primary completion and estimated study completion dates are not specified, but the latest update was submitted on June 16, 2025, indicating ongoing progress.
Market Implications: The progress of this study could significantly impact Aurinia Pharmaceuticals’ stock performance, as positive results may enhance investor confidence and market position. The study’s outcomes could also influence the competitive landscape in lupus nephritis treatment, given the limited options for young patients.
The study is ongoing, with further details available on the ClinicalTrials portal.